Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Journal of Health Politics, Policy and Law 1995 20(4):973-1000; DOI:10.1215/03616878-20-4-973
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mowery, D. C.
Right arrow Articles by Mitchell, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Duke University Press

Improving the Reliability of the U.S. Vaccine Supply: An Evaluation of Alternatives

David C. Mowery
University of California, Berkeley and Canadian Institute for Advanced Research

Violaine Mitchell
Institute of Medicine

Since taking office, President Clinton has devoted considerable attention to childhood immunization and to the overall U.S. policy toward vaccine development, delivery, and pricing. But the reliability of U.S. vaccine supplies has received far less attention, despite several recent interruptions in vaccine production and supply. Moreover, the increasing producer concentration in the U.S. and global vaccine industries raises the possibility that more and more important vaccines will be produced by a single firm, often in a single production facility. Is a federal policy for vaccine supply assurance necessary, and what form should it take? Are sole-source suppliers a weak link in the U.S. vaccine supply chain? Are the recommendations of the Institute of Medicine’s Committee on Emerging Infections for a publicly owned "standby production capacity" of critical vaccines feasible or cost-effective? We consider these and other issues in our discussion of the U.S. vaccine industry, the potential role of foreign vaccine suppliers, and the use of existing federal facilities and policies to address a possible interruption in critical vaccine supplies.




This article has been cited by other articles:


Home page
Journal of Health Politics, Policy and LawHome page
D. Ridgway
No-Fault Vaccine Insurance: Lessons from the National Vaccine Injury Compensation Program
Journal of Health Politics Policy and Law, January 1, 1999; 24(1): 59 - 90.
[Abstract] [PDF]




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 1995 by Duke University Press